La vendita allo scoperto per Santen Pharmaceutical dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Santen Pharmaceutical. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Santen Pharmaceutical (OTC:SNPHY) Azioni, Report sulle vendite allo scoperto

SANTEN PHARMACEUTICA

Santen Pharmaceutical

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

SANTEN PHARM CO UNSP/ADR by Santen Pharmaceutical Co., Ltd.

Santen Pharmaceutical Co Ltd

Catalent, Inc. (CTLT) recently faced a setback, witnessing a 6.1% dip in its stock value over the last month. However, in the light of the recent release of its first quarter results of fiscal 2024, can the company reverse its fortune? Keep reading… A prominent player in the pharmaceutical and biotech industry with a market cap of $7.14 billion, Catalent, Inc. (<a href="https://stocknews.com/stock/CTLT/">CTLT</a>) specializes in the development and manufacturing of solutions for a wide range of products, including drugs, protein-based biologics, cell and gene therapies, and consumer health items on a global scale.
CTLT operates in several segments within the pharmaceutical and healthcare industry, including Softgel and Oral Technologies; Biologics; Oral and Specialty Delivery; and Clinical Supply Services. In addition, it extends its services to other healthcare market segments, such as animal health, medical devices, and cosmetics industries.
After CTLT <a href="https://www.reuters.com/business/catalent-delays-quarterly-filing-with-sec-700-mln-impairment-charge-2023-11-14/">announced a postponement in its quarterly filing</a> with the U.S. Securities and Exchange Commission (SEC) owing to a <a href="https://www.investopedia.com/terms/g/goodwill-impairment.asp">goodwill impairment</a> charge of approximately $700 million, the company declared its fiscal first-quarter results on November 15, 2023.
The drug manufacturing delayed its annual results several times this year on account of production snags. In August, the company postponed its annual filing, citing the need for an "assessment of internal controls" pertaining to its financial reporting for the year.
Nevertheless, despite exceeding analyst estimates, the company's earnings report for the first quarter revealed a drop in its revenue and major losses. Notably, the Biologics segment saw a 16% decline in net revenue compared to the previous year's quarter.
Furthermore, as of September 30, 2023, CTLT's total debt increased to $4.95 billion. The net leverage ratio for the same period rose to 7.4x, reflecting an increase from 6.4x on June 30, 2023, and a significant jump from 3.2x as of September 30, 2022.
On top of it, the dynamics of institutional investment in CTLT have seen recent shifts. Of the 510 institutional holders, <a href="https://www.nasdaq.com/market-activity/stocks/ctlt/institutional-holdings">235 have opted to reduce their positions</a> in the stock, and 78 holders have entirely liquidated their positions. This indicates a changing sentiment among institutional investors regarding their stake in CTLT.
CTLT's shares have plunged 41.5% over the past nine months and 6.1% over the past month to close the last trading session at $39.60.
Here are the factors that could affect CTLT's performance in the near term:
Weak Financials
For the fiscal first quarter that ended on September 30, 2023, CTLT's net revenues plunged 3.9% from the year-ago value to $982 million, while the company's operating loss amounted to $735 million versus operating earnings of $60 million in the prior-year quarter.
Furthermore, during the same period, the company's net loss came in at $715 million and $3.94 per share. Its adjusted EBITDA decreased 38.5% from the year-ago value to $115 million. Also, its cash and cash equivalents stood at $209 million, declining 25.5% compared to $280 million as of June 30, 2023.
Poor Profitability
The stock's trailing-12-month negative levered FCF margin of 4.18% compares to the 0.11% industry average. Likewise, its trailing-12-month negative EBIT margin of 0.52% compares to the industry average of 0.61%. Furthermore, CTLT's trailing-12-month gross profit margin of 23.21% is 59% lower than the 56.62% industry average.
Unfavorable Analyst Estimates
Street expects revenue for the fiscal second quarter (ending December 2023) to decline 11.3% year-over-year to $1.02 billion, while its EPS for the same period is projected to come in at a negative $0.02. In addition, its EPS for the fiscal period ending June 2024 is expected to register a decline of 25.3% year-over-year.
High Valuation
In terms of forward non-GAAP P/E, CTLT is trading at 52.84x, 189.6% higher than the industry average of 18.25x. Likewise, its forward EV/EBITDA multiple of 16.34 is 26.9% higher than the industry average of 12.88. Furthermore, its forward Price/Cash Flow multiple of 21.57 is 34.8% higher than the industry average of 16x.
POWR Ratings Exhibit Bleak Prospects
CTLT's weak fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of D, translating to a Sell in our proprietary rating system. The POWR Ratings are calculated by accounting for 118 distinct factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. CTLT has a D grade for Momentum in sync with the stock currently trading below its 50-day moving average of $41.72 and 200-day moving average of $48.63.
Moreover, the stock has a D grade for Sentiment and Quality, justified by its bleak analyst estimates and poor profitability.
Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, CTLT is ranked #133 out of the 150 stocks.  
Beyond what we've stated above, we have also rated the stock for Growth, Value, and Stability. Get all ratings of CTLT <a href="https://stocknews.com/stock/CTLT/">here</a>.
Bottom Line
Despite the consistent demand for pharmaceuticals driven by the ongoing necessity for medications and treatments, CTLT faces challenges such as weak financial performance, poor profitability, an elevated valuation, and negative sentiments among analysts.
These factors collectively cast a cautious shadow on the outlook for the stock's future performance. Thus, potentially avoiding investment in CTLT may be prudent for investors.  
How Does Catalent, Inc. (CTLT) Stack Up Against Its Peers?   
While CTLT has an overall grade of D, equating to a Sell rating, you may also check out these other stocks within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry: Santen Pharmaceutical Co., Ltd. (<a href="https://stocknews.com/stock/SNPHY/">SNPHY</a>), Taro Pharmaceutical Industries Ltd. (<a href="https://stocknews.com/stock/TARO/">TARO</a>), and AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV/">ABBV</a>), with an A (Strong Buy) rating. For exploring more Medical - Pharmaceuticals stocks, <a href="https://stocknews.com/category/pharmaceuticals/">click here</a>.     
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
CTLT shares were trading at $40.00 per share on Friday morning, up $0.40 (+1.01%). Year-to-date, CTLT has declined -11.13%, versus a 20.31% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Anushka Mukherjee</h2> <img src='https:/wp-content/uploads/2023/06/Anushka-Mukherjee_Headshot-2.jpg' style="float:left; padding:5px;width:125px;">Anushka's ultimate aim is to equip investors with essential knowledge that empowers them to make well-informed investment choices and attain sustained financial prosperity in the long run.<a href="https://stocknews.com/authors/?author=anushka-mukherjee">More...</a>The post <a href=https://stocknews.com/news/ctlt-snphy-taro-abbv-catalent-ctlt-loses-6-1-over-the-past-month-can-the/>Catalent (CTLT) Loses 6.1% Over the Past Month: Can the Stock Reverse Its Fortune?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Catalent (CTLT) Loses 6.1% Over the Past Month: Can the Stock Reverse Its Fortune?

As Pfizer (PFE) navigates a post-pandemic world with a shifting focus away from COVID-related products, what should investors expect from this pharma giant? Let's look at its financial metrics to know more… Pfizer Inc. (<a href="https://stocknews.com/stock/PFE">PFE</a>) is dealing with weakening demand for its COVID antiviral treatment Paxlovid and the COVID vaccine. Due to the weakening demand for its COVID-related products, the company recorded an adjusted loss per share of $0.17 in the third quarter, while its $13.23 billion revenue <a href="https://www.cnbc.com/2023/10/31/pfizer-pfe-q3-earnings-report-2023.html">missed the analyst-expected figure</a> of $13.34 billion.
However, PFE is looking to shift its focus away from COVID-19 to other growth opportunities. The company's CEO, Albert Bourla, noted that the company is nearing its target of launching 19 new products or drug indications in an 18-month span. It is <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/how-pfizer-is-fortifying-growth-beyond-covid-products-2023-12-13/">also focusing on</a> acquisitions, such as a $43 billion acquisition of drug-making company Seagen, as well as cost-cutting measures.
While the company navigates a post-pandemic backdrop, it might be wise to wait for a better entry point in the stock. Let's look at the trends of its key financial metrics to gain further insight.
Analyzing Pfizer Inc.'s Financial Performance from 2020 to 2023: Trends and Fluctuations
The trend of PFE's trailing-12-month net income from the end of 2020 to late 2023 shows clear fluctuations but an overall upward growth, with a significant drop in the last reported quarter:
<ul>
<li style="font-weight: 400;" aria-level="1">At the end of December 2020, the net income was $9.62 billion.</li>
<li style="font-weight: 400;" aria-level="1">This value then showed a stable increase throughout the following years, reaching its peak at $31.37 billion at the end of December 2022, representing an astonishing 227% growth from 2020.</li>
<li style="font-weight: 400;" aria-level="1">The upward trend continued until the second quarter of 2022, when the net income dropped slightly to $29.77 billion in April 2023 before plunging drastically to $10.48 billion by October 2023, a sharp decrease of nearly 65% from its peak.</li>
</ul>
The net income increased significantly from $9.62 billion at the end of 2020 to its high point of $31.37 billion in just two years despite the substantial decline toward the end of 2023. This demonstrates that despite dramatic fluctuations, the overall trend for PFE's net income showed considerable growth before the recent drop.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1703843807.66966.png" />
PFE has demonstrated substantial fluctuations in its trailing-12-month revenue over the past years. Here are key points to consider:
<ul>
<li style="font-weight: 400;" aria-level="1">PFE closed 2020 with revenue of $41.91 billion.</li>
<li style="font-weight: 400;" aria-level="1">By April 2021, the revenue had grown to $44.46 billion, representing a noticeable surge in a span of four months.</li>
<li style="font-weight: 400;" aria-level="1">The revenue continued on an escalatory trend, reaching its peak by December 31, 2022, when it reached $100.33 billion.</li>
<li style="font-weight: 400;" aria-level="1">This indicated a significant growth rate when compared with the initial value and marked the highest point for the company's revenue.</li>
<li style="font-weight: 400;" aria-level="1">However, after this high point, PFE has been experiencing a decline in its revenue with each passing quarter of 2023. The last reported revenue in October 2023 was $68.54 billion, substantially less than the peak value recorded.</li>
</ul>
It's vital to note that these trends and fluctuations represent the company's performance dynamics over time. The recent decline in revenues may necessitate further examination into the factors contributing to these apparent downturns.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1703843875.84617.png" />
The series presents a summary of the fluctuations of PFE's gross margin over a span from December 2020 to October 2023.
<ul>
<li style="font-weight: 400;" aria-level="1">As of December 31, 2020, PFE's gross margin stood at 79.30%.</li>
<li style="font-weight: 400;" aria-level="1">It then dipped to 76.30% on April 4, 2021, and further dropped to 70.40% by July 4, 2021.</li>
<li style="font-weight: 400;" aria-level="1">The gross margin showed continued decline in subsequent months, reaching 64.20% in October 2021 and 62.10% by the end of the year.</li>
<li style="font-weight: 400;" aria-level="1">In the first half of 2022, gross margin decreased to a low of 60.40% before beginning an upward trend in July, rising to 62.20% and then to 65.60% by October 2nd.</li>
<li style="font-weight: 400;" aria-level="1">By the end of 2022, the gross margin was slightly higher, at 65.80%, indicating a slowdown in the rate of rise.</li>
<li style="font-weight: 400;" aria-level="1">In 2023, the gross margin continued its upward trend in the first half, reaching 68.50% in April and 69.40% in July before falling drastically to 60.50% in October.</li>
</ul>
The data shows a general downward trend for PFE's gross margin between 2020 and 2021. In 2022, the gross margin started to recover, but the improvement has been somewhat inconsistent. Overall, the gross margin experienced a growth rate of -18.80%, measured from the initial value in December 2020 to the latest reading in October 2023.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1703843899.44215.png" />
Based on the data provided, PFE showed a general upward trend in its <a href="https://www.investopedia.com/terms/a/assetturnover.asp">asset turnover</a> from December 2020 to July 2022. However, after that period, there was a marked downturn.
<ul>
<li style="font-weight: 400;" aria-level="1">Starting at 0.247 in December 2020, PFE's asset turnover rose steadily until reaching a peak of 0.547 in July 2022.</li>
<li style="font-weight: 400;" aria-level="1">From this peak, there was a small dip to 0.527 in October 2022, which held roughly stable at 0.52 by the end of December 2022.</li>
<li style="font-weight: 400;" aria-level="1">Unfortunately, the asset turnover then declined sharply in 2023, dropping to 0.475 by April, further to 0.386 by July, and down to 0.331 by October.</li>
</ul>
In terms of the growth rate measured from the first to the last value in the series, there was an increase of approximately 34%. That said, it's important to note that most of this growth occurred before July 2022, with a noticeable decline after that.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1703844090.20149.png" />
Six-Month Decline: Chronicling Pfizer Inc.'s Share Price Fluctuations in the Second Half of 2023
The share prices of PFE have demonstrated notable fluctuations over the span of six months, from July 2023 to the end of December 2023. Key observations:
<ul>
<li style="font-weight: 400;" aria-level="1">The share price on July 7, 2023, was $36.15. Over the course of the month, it saw a negligible decrease and then an increase, ending at $36.92 by July 28, 2023.</li>
<li style="font-weight: 400;" aria-level="1">An initial fall in August 2023 was witnessed, with the share price dropping to $35.52 by August 4, 2023. After that slight dip, the stock began a steady climb to reach $36.65 by August 25, 2023.</li>
<li style="font-weight: 400;" aria-level="1">Starting September 2023, a clear and constant decelerating trend was observed. The share price fell steadily from $35.96 on September 1, 2023, to $32.51 by the end of the month on September 29, 2023.</li>
<li style="font-weight: 400;" aria-level="1">This decelerating trend continued through October 2023 - the share price further slid down to $30.74 by October 27, 2023.</li>
<li style="font-weight: 400;" aria-level="1">In November 2023, the shares' values hovered around the low 30s and higher 20s, with a notable drop to $29.62 by November 17, 2023. The sharing price ended slightly higher at $30.26 by November 24, 2023.</li>
<li style="font-weight: 400;" aria-level="1">A significant deceleration was observed in December 2023. The share price began at $29.86 on December 1, 2023, and steadily declined to $27.30 by December 15, 2023. Although the stock recovered a bit, closing at $28.79 by the end of the month (December 28, 2023), this still signifies a notable decrease compared to the beginning of the month.</li>
</ul>
In conclusion, over these six months, the share price of PFE demonstrated a clear decelerating trend, especially prominent from September onward. This trend reached its lowest point in mid-December 2023 before showing a slight recovery toward the end of the year. Here is a chart of PFE's price over the past 180 days.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1703844192.28449.png" />
Assessing Pfizer's Performance: High Value but Decreasing Stability and Quality Ratings
Based on the provided data, PFE's latest <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> grade is a C (Neutral). As of the most recent date in the data, December 29, 2023, it ranks #67 in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> category, which comprises a total of 156 stocks.
The C (Neutral) grade and ranking reflect a relatively middle-of-the-road performance compared to other stocks within the same category. The company's POWR grade and rank within the category have somewhat fluctuated throughout the year:
<ul>
<li style="font-weight: 400;" aria-level="1">In July 2023, PFE maintained a steady POWR grade of C (Neutral), ranking #40 at its best and #44 at its worst.</li>
<li style="font-weight: 400;" aria-level="1">By August, while the grade remained a C (Neutral), the rank had slipped to #59 in the category.</li>
<li style="font-weight: 400;" aria-level="1">Throughout September, the ranking ranged from #59 to #64.</li>
<li style="font-weight: 400;" aria-level="1">In October, the rank fluctuated between #63 and #66 in its category.</li>
<li style="font-weight: 400;" aria-level="1">By November, the ranking had dropped to as low as #74, although it recovered somewhat by the month's end.</li>
<li style="font-weight: 400;" aria-level="1">Ultimately, in December, PFE ended with a ranking of #67 in the Medical - Pharmaceuticals category of stocks.</li>
</ul>
It is worth noting that having a C (Neutral) grade suggests average performance. However, the shift in rankings, particularly the downward trend in the latter half of the year, may be an area to further investigate for potential factors impacting performance.
Based on the data given, the three most noteworthy POWR Ratings dimensions for PFE are Value, Stability and Quality. Here's how these dimensions are rated over time:
Value:
<ul>
<li style="font-weight: 400;" aria-level="1">PFE had its highest Value rating in July 2023 with a score of 99.</li>
<li style="font-weight: 400;" aria-level="1">Although it decreased marginally each subsequent month, it remains consistently high, with ratings barely dipping below the 90s till December 2023.</li>
</ul>
Stability:
<ul>
<li style="font-weight: 400;" aria-level="1">The Stability rating started at 62 in July 2023, slightly dipped to 60 from August to September 2023, continued to decrease to 56 in October and dropped further to 50 by December 2023.</li>
<li style="font-weight: 400;" aria-level="1">This suggests a clear downward trend in the Stability dimension over this period.</li>
</ul>
Quality:
<ul>
<li style="font-weight: 400;" aria-level="1">Starting at 74 in July 2023, the Quality rating of PFE experienced a somewhat steady decline throughout the given timeframe, reaching a low of 50 in November before slightly increasing to 53 in December 2023.</li>
<li style="font-weight: 400;" aria-level="1">This indicates a gradual decreasing trend in the Quality dimension over this period.</li>
</ul>
The progressive decrease in ratings for Stability and Quality dimensions reflects some concerning trends for PFE. On the other hand, the company's Value dimension maintains a high rating throughout the observed period, speaking to its perceived financial strength.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1703844245.55644.png" />
How does Pfizer Inc. (PFE) Stack Up Against its Peers?
Other stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> sector that may be worth considering are Taro Pharmaceutical Industries Ltd. (<a href="https://stocknews.com/stock/TARO">TARO</a>), Santen Pharmaceutical Co., Ltd.  (<a href="https://stocknews.com/stock/SNPHY">SNPHY</a>), and AbbVie Inc. (<a href="https://stocknews.com/stock/ABBV">ABBV</a>) - they have better POWR Ratings. <a href="https://stocknews.com/category/pharmaceuticals/">Click here</a> to explore more Medical - Pharmaceuticals stocks.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
PFE shares were trading at $28.65 per share on Friday morning, down $0.14 (-0.49%). Year-to-date, PFE has declined -41.55%, versus a 25.80% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Anushka Dutta</h2> <img src='https:/wp-content/uploads/2021/08/Anushka-Dutta_Headshot_3.jpg' style="float:left; padding:5px;width:125px;">Anushka is an analyst whose interest in understanding the impact of broader economic changes on financial markets motivated her to pursue a career in investment research.<a href="https://stocknews.com/authors/?author=anushka-dutta">More...</a>The post <a href=https://stocknews.com/news/pfe-taro-snphy-abbv-pfizer-pfe-2024-preview-what-to-expect-from-the-pharma/>Pfizer (PFE) 2024 Preview: What to Expect From the Pharma Stock?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Pfizer (PFE) 2024 Preview: What to Expect From the Pharma Stock?

Tilray Brands (TLRY) posted record net revenue in its most recent quarter. So, is this the right entry point in the stock? Let's analyze some of its key financial metrics to gauge its prospects... In the second fiscal quarter, Tilray Brands, Inc. (<a href="https://stocknews.com/stock/TLRY/">TLRY</a>) reported a record net revenue of $194 million. This reflects an impressive surge of 34% compared to the same period in the previous year, primarily attributed to robust sales in their cannabis and beverage sector.
Despite nearing break-even profitability with an adjusted loss per share of zero, the company recorded a net loss of $2.70 million adjusted for the quarter at the bottom line.
Furthermore, the Adjusted EBITDA for the second quarter was reported at $10.10 million, in contrast to $11 million in the same quarter of the past year. This primarily stems from the HEXO advisory fee revenue of the previous year's quarter combined with timing differences recognizing synergies following recent acquisitions.
The gross profit margins experienced a slump in both the cannabis and beverage alcohol segments, dropping by 12 percentage points to 31% in the former and by 13 percentage points to 34% in the latter.
In light of the underwhelming bottom-line performance, potential investors might want to exercise caution with TLRY. Further scrutiny of its fundamental performance indicators could offer deeper insights into the company's financial health.
Unpacking Financial Performance of TLRY: Trends, Growth Rates and Market Signals from 2021 to 2023
The trend and fluctuation of the trailing-12-month Net Income of TLRY have been negatively significant over the time series. Below is a breakdown of the series:
<ul>
<li>As of March 31, 2021, TLRY reported a Net Income deficit of -$427.91 million.</li>
<li>As we progress to May 31, 2021, there was a slight improvement as the deficit reduced to -$367.42 million.</li>
<li>A year later, as of May 31, 2022, we noted an increase in the Net Income deficit to -$476.8 million.</li>
<li>By August 31, 2022, the reported Net Income showed a further shortfall of -$508.63 million.</li>
<li>As of November 30, 2022, there was an alarming increase in the deficit to -$577.9 million.</li>
<li>The downturn got worse as the Net Income registered a massive shortage of -$1.792 billion on February 28, 2023.</li>
<li>There was a slight relief as the figures reported for May 31, 2023, came to -$1.4526 billion.</li>
<li>This negligible relief continued into August 31, 2023, with a reported Net Income deficit of -$1.4507 billion.</li>
<li>Ending the series on a relatively hopeful note, November 30, 2023, saw a deficit of -$1.4302 billion.</li>
</ul>
Clearly, the trends for TLRY's Net Income heavily favor a negative growth over this period. The deficit increased from -$427.91 million on March 31, 2021, to -$1.4302 billion on November 30, 2023. This reflects a tremendous negative growth rate. Prioritizing the recent data, the deficit appears to have decelerated slightly but still remains significantly high.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1705076899.35316.png" />
The trailing-12-month revenue of TLRY over the period from March 2021 to November 2023 has shown a general upward trend with some fluctuations.
<ul>
<li>In March 2021, the revenue was at $206.4 million.</li>
<li>By May 2021, it had more than doubled to $513.1 million.</li>
<li>In May 2022, revenue peaked at $628.37 million, but started fluctuating downward in the later part of 2022 with $613.56 million in August and continued to slide to $602.54 million in November 2022 and $596.26 million in February 2023.</li>
<li>However, beginning from May 2023, the revenue began to climb again reaching $627.12 million, and by August 2023 it was up to $650.86 million.</li>
<li>The last recorded value in this series is from November 2023, where we see the highest point of $700.49 million.</li>
</ul>
The overall growth rate from the first recorded value in March 2021 to the last in November 2023 is approximately 239%, indicating an overall positive trajectory for TLRY's financial performance despite experiencing some periods of contraction within this period.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1705076935.69044.png" />
The trend and fluctuations of TLRY's ROA can be summarized as follows:
<ul>
<li>The ROA for the publicly traded US company, TLRY, shows a negative trend over the period from March 2021 to November 2023.</li>
<li>On March 31, 2021, the ROA was -44.4%. Despite a sharp improvement to -8.3% by May 31, 2022, it has progressively worsened since, with occasional fluctuations.</li>
<li>Briefly, there was a marginal decline from May 31, 2022, to August 31, 2022, with ROA slipping from -8.3% to -9%. ROA slightly dropped again to -10.3% on November 30, 2022.</li>
<li>A significant downward shift occurred by February 28, 2023, with the ROA deteriorating drastically to -34.3%.</li>
<li>From February to May 2023, ROA showed signs of recovery, improving from -34.3% to -29.4%.</li>
<li>This recovery was short-lived, with ROA dipping down to -31.3% on August 31, 2023, and further declining to -32.8% by November 30, 2023.</li>
<li>Comparing the first and last values in the series, there is a decrease of 11.6%, indicating a negative growth rate over the period.</li>
</ul>
Greater emphasis should be placed on the more recent data, which exhibits a continuous downward trend. The last recorded ROA of -32.8% on November 30, 2023, highlights this concerning downward trajectory.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1705077003.74328.png" />
The <a href="https://www.investopedia.com/terms/c/currentratio.asp">Current Ratio</a> trend and fluctuations of TLRY over the specified timeframe can be summarized as follows:
Overall  Trend: 
From March 2021 through November 2023, TLRY's Current Ratio exhibits a fluctuating pattern with a slight decline in the overall trend.
Yearly insights:
<ul>
<li>2021: The Current Ratio opened at 2.01 as of March 31. By May, TLRY's ratio increased to 2.20. However, there was a decline to 1.60 by August. In November, a significant rise occurred, reaching 2.25.</li>
<li>2022: This upward trend continued into the following year, peaking at 3.33 in August from 2.46 in February. But by the end of November, it dropped significantly to 1.91 owning to potential economic or operational conditions.</li>
<li>2023: Throughout 2023, the Current Ratio sees a relatively stable fluctuation between 1.54 and 1.78, with the final number in November at 1.62.</li>
</ul>
Growth Rate: 
Comparing the first recorded value in March 2021 (2.01) and the last value in November 2023 (1.62), the Current Ratio decreased by approximately 19.4%. Important note about Current Ratio: 
It's crucial to mention that the Current Ratio is a liquidity ratio that measures a company's ability to cover its short-term obligations with its short-term assets. A higher Current Ratio can indicate more financial flexibility, while a lower ratio might signal potential liquidity issues. This data should be considered along with other financial indicators and business context for reliable assessment.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1705077029.39146.png" />
The Analyst Price Target for TLRY shows a steady downward trend from November 2021 to January 2024. Notable fluctuations include:
<ul>
<li>In November 2021, the Analyst Price Target started at $12.79.</li>
<li>By the end of 2021, it slightly decreased to $12.24.</li>
<li>There was a significant drop to $9.00 in February 2022.</li>
<li>From April to June 2022, the decline slowed down slightly, moving from $8.52 to $7.70.</li>
<li>A larger drop occurred between June and August 2022, landing at $4.35 by the end of August.</li>
<li>Then, from August 2022 to November 2022, the value saw minimal decreases, hovering around $4.00 area.</li>
<li>Entering 2023, the figure continued to decrease, falling from $3.95 in December 2022 to $3.00 in May 2023 and maintaining this level until July 2023.</li>
<li>Toward the end of 2023 and leading into early 2024, the value fell further to $2.38 and held constant into the early days of 2024.</li>
</ul>
Overall, the series displays a long-term downward trend with some periods of short-term stabilization. The growth rate, calculated by comparing the last value ($2.38) from the first value ($12.79), indicates a decrease of roughly 81% over the specified period. Please note that even within a general descending trend, there are intermittent periods of slower declines or stability is indicative of the target price's susceptibility to short-term market conditions while primarily obeying the longer term downward direction. The data ending in January 2024 demonstrates that this analysis places a greater emphasis on the most recent performance of TLRY's Analyst Price Target.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1705077129.79604.png" />
Analyzing TLRY Share Price Trends: Peaks, Dips and Recovery in 2023-24
Analyzing the provided TLRY share price data reveals a few discernible trends:
<ul>
<li>Starting from July 21, 2023, when the share price was $1.69, there was a stiff upward trend through to September 15, 2023, when it peaked at $3.05</li>
<li>This upward trend had an acceleration during early August 2023, with the share price quickly growing from $1.96 on July 28, 2023, to $2.65 by August 11, 2023.</li>
<li>From mid-September 2023 through October 2023, there was a clear downward trend. By October 27, 2023, the share price had fallen to $1.81, representing a significant deceleration from its previous peak.</li>
<li>In November 2023, the share price remained relatively static, fluctuating around the $1.8 range before demonstrating a slow and steady upward trend from December 2023 into early January 2024.</li>
<li>By January 11, 2024 the share price had reached $2.10, a reduction from a high of $2.32 at the end of December 2023, indicating a possible deceleration in growth.</li>
</ul>
Over the overall period examined (from July 2023 through January 2024), the share price demonstrates periods of sharp growth followed by steeper declines and a final phase of slow recovery. The fastest growth can be observed in late July - early August 2023, and the hardest decline can be seen from mid-September 2023 through October 2023. After that, the rate of change gets milder. Here is a chart of TLRY's price over the past 180 days.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1705077196.2028.png" />
Exploring TLRY Stock's Growth, Momentum and Value Dimensions: A POWR Ratings Analysis
TLRY has an overall F rating, translating to a Strong Sell in our <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> system. It is ranked #149 out of the 161 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> category.
The POWR Ratings provide a broad assessment of a stock's overall viability and potential performance, considering certain crucial perspectives. We'll focus on the three most notable dimensions for TLRY based on the supplied data: Growth, Momentum, and Value.
Growth: This dimension consistently performed the highest across the multiple time frames. In July 2023, the Growth rating was 72, and it showed a considerable increase to 88 by August 2023. It slightly declined in the following months, hitting 76 in December 2023, but picked up again to 79 by January 12, 2024.
Momentum: The Momentum score presents an apparent upward trend. Although starting from a low rating of 0 in July 2023, it increased to 13 by August 2023. This upward trend continued to hold through the months, with minor fluctuations, reaching 22 by January 12, 2024.
Value: The Value dimension showed some inconsistencies over the period. Initially, in July 2023, it had a value of 5 which gradually increased to 12 by November 2023. It then mildly declined to 8 by January 12, 2024. In conclusion, the growth aspect for TLRY appears the most promising, being the highest-rated dimension throughout. There are clear upward trends in the momentum aspect. On the other hand, the value seems volatile without a clear pattern in its trend.
<img src="https://storage.googleapis.com/sjn-charts/visualized-metrics/1705077257.00302.png" />
How does Tilray Brands, Inc. (TLRY) Stack Up Against its Peers?
Other stocks in the Medical - Pharmaceuticals sector that may be worth considering are SANTEN PHARMACEUTICAL CO., LTD. (<a href="https://stocknews.com/stock/SNPHY">SNPHY</a>), Novo Nordisk A/S (<a href="https://stocknews.com/stock/NVO">NVO</a>), and Bristol-Myers Squibb Company (<a href="https://stocknews.com/stock/BMY">BMY</a>) -- they have better POWR Ratings.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
TLRY shares were trading at $1.86 per share on Friday afternoon, down $0.04 (-2.11%). Year-to-date, TLRY has declined -19.13%, versus a 0.36% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Subhasree Kar</h2> <img src='https:/wp-content/uploads/2021/06/Subhasree-Kar-HS2.jpg' style="float:left; padding:5px;width:125px;">Subhasree's keen interest in financial instruments led her to pursue a career as an investment analyst. After earning a Master's degree in Economics, she gained knowledge of equity research and portfolio management at Finlatics.<a href="https://stocknews.com/authors/?author=subhasree-kar">More...</a>The post <a href=https://stocknews.com/news/tlry-snphy-nvo-bmy-tilray-brands-tlry-earnings-spotlight-buy-or-sell/>Tilray Brands (TLRY) Earnings Spotlight -- Buy or Sell?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Tilray Brands (TLRY) Earnings Spotlight -- Buy or Sell?

Pharmaceutical powerhouse Johnson & Johnson (JNJ) is proactively driving innovation throughout the healthcare spectrum, thanks to its strong focus on innovative medicines and MedTech solutions. However, with the company's fiscal fourth-quarter earnings on the horizon, could the stock be a wise portfolio addition? Keep reading to find out… Boasting a market cap of $389.21 billion, leading pharma giant Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>) is all set to lift the curtains on its fourth-quarter results (ended December 2023) on January 23, 2024. Thus, this article sheds light on the fundamentals of JNJ to determine the stock's worthiness as an investment candidate. Let's understand in detail.
While JNJ's third-quarter profit remained flat year-over-year, its top line, on the other hand, witnessed solid year-over-year growth. The company topped its Wall Street revenue and EPS estimates for the same quarter. Additionally, its EPS boasts an admirable track record of consistently outperforming Street estimates in each of the trailing four quarters.
Moreover, JNJ's pharmaceutical sales for the third quarter rose 5.1% year-over-year to $13.89 billion, <a href="https://www.cnbc.com/2023/10/17/johnson-johnson-jnj-q3-earnings-report-2023.html">exceeding Wall Street's estimate</a> of $13.34 billion. The company's impressive pharmaceutical sales growth can be attributed to the success of its key products, including Darzalex, used for the treatment of multiple myeloma, and Erleada, employed in addressing prostate cancer and various oncology treatments.
Notably, JNJ's blockbuster drug Stelara, known for its efficacy in treating immune-mediated inflammatory diseases, also played a pivotal role in driving this upward trajectory.
Meanwhile, the company's MedTech segment, which engages in the sale of medical devices, rose to nearly $7.46 billion, up 10% year-over-year, spurred by the acquisition of Abiomed, a cardiovascular medical technology firm, on December 22, 2022.
On top of it, sales of JNJ's MedTech segment were further bolstered by its electrophysiological products for assessing the heart's electrical system, wound closure products, orthopedic trauma devices, and contact lenses.
The drugmaker further solidified its position through the acquisition of Ambrx Biopharma, Inc. (<a href="https://stocknews.com/stock/AMAM/">AMAM</a>), a clinical-stage biopharmaceutical company, on January 8, 2024. AMAM's promising pipeline of clinical and preclinical programs, particularly in prostate and breast cancer, aligns with JNJ's goal of providing transformative cancer treatment.
The acquisition enhances JNJ's oncology portfolio, offering targeted therapies with reduced side effects, and underscores its commitment to advancing precision biologics for improved patient outcomes.
Furthermore, on January 2, 2024, JNJ's Board of Directors declared a quarterly dividend of $1.19 per share, payable to its shareholders on March 5, 2024. The company's annual dividend of $4.76 translates to a 2.94% yield on the prevailing prices, while its four-year average dividend yield is 2.64%.
Its dividend payouts have grown at CAGRs of 5.7% and 5.8% over the past three and five years, respectively. Also, JNJ has a record of 61 years of consecutive dividend growth. In terms of price performance, JNJ's shares have soared 6.2% over the past three months and 3.3% over the past month to close the last trading session at $161.68.
Here are the financial aspects of JNJ that could influence its performance in the near term:
Strong Financials
JNJ's sales to customers for the third quarter (ended October 1, 2023) increased 6.8% year-over-year to $21.35 billion, while its gross profit rose 6.7% from the prior-year quarter to $14.75 billion. The company's adjusted net earnings from continuing operations grew 14.1% year-over-year to $6.78 billion. In addition, its adjusted EPS came in at $2.66, up 19.3% from the year-ago value.
Robust Profitability
JNJ's trailing-12-month EBIT and levered FCF margins of 27.97% and 21.46% are significantly higher than the 0.41% and 0.29% industry averages, respectively. Its trailing-12-month cash per share of $8.20 is 549.9% higher than the $1.26 industry average. Furthermore, the stock's trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda-margin.asp">EBITDA margin</a> of 35.49% is 567.8% higher than the 5.31% industry average.
Discounted Valuation
In terms of forward non-GAAP P/E, JNJ is trading at 16.31x, 15.9% lower than the industry average of 19.40x. Likewise, its forward EV/EBITDA multiple of 12.52 is 6.9% lower than the industry average of 13.45. Furthermore, its forward EV/EBIT multiple of 14.18 is 18% lower than the industry average of 17.29x.
POWR Ratings Exhibit Solid Prospects
JNJ's robust fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, translating to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by accounting for 118 distinct factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. JNJ has a B grade for Value justified by its discounted valuation. Likewise, its B grade for stability is in sync with its 24-month beta of 0.33. Moreover, the stock's B grade for Quality is consistent with its higher-than-industry profitability metrics.
Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, JNJ is ranked #10 out of the 162 stocks.
Beyond what we've stated above, we have also rated the stock for Growth, Momentum, and Sentiment. Get all JNJ ratings <a href="https://stocknews.com/stock/JNJ/">here</a>.
Bottom Line
As JNJ continues to drive innovation in the healthcare space through ground-breaking solutions and strategic acquisitions, the company emerges as an enticing investment opportunity, supported by its impressive financial performance in the third quarter and high profitability. Moreover, the added factor of an attractive valuation and dividend yield further solidifies its appeal as a sound investment choice.  
How Does Johnson &amp; Johnson (JNJ) Stack Up Against Its Peers? 
While JNJ has an overall grade of A, equating to a Strong Buy rating, you may also check out these other stocks within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry: Novartis AG (<a href="https://stocknews.com/stock/NVS/">NVS</a>), Novo Nordisk A/S (<a href="https://stocknews.com/stock/NVO/">NVO</a>), and Santen Pharmaceutical Co., Ltd. (<a href="https://stocknews.com/stock/SNPHY/">SNPHY</a>), with an A (Strong Buy) rating. For exploring more Medical - Pharmaceuticals stocks, <a href="https://stocknews.com/category/pharmaceuticals/">click here</a>.  
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
JNJ shares were trading at $162.22 per share on Monday afternoon, up $0.54 (+0.33%). Year-to-date, JNJ has gained 3.50%, versus a 1.81% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Anushka Mukherjee</h2> <img src='https:/wp-content/uploads/2023/06/Anushka-Mukherjee_Headshot-2.jpg' style="float:left; padding:5px;width:125px;">Anushka's ultimate aim is to equip investors with essential knowledge that empowers them to make well-informed investment choices and attain sustained financial prosperity in the long run.<a href="https://stocknews.com/authors/?author=anushka-mukherjee">More...</a>The post <a href=https://stocknews.com/news/jnj-nvs-nvo-snphy-amam-johnson-johnson-jnj-analyzing-signals-before-quarterly-earnings/>Johnson & Johnson (JNJ): Analyzing Signals Before Quarterly Earnings</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Johnson & Johnson (JNJ): Analyzing Signals Before Quarterly Earnings

Pfizer (PFE) is facing hurdles due to weakened demand for its products and pipeline diversification challenges. Nevertheless, the company exhibits long-term potential through strategic acquisitions. Given this scenario, what course of action should be considered ahead of the upcoming earnings release? Read more to find out... Analysts expect Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>) to report poor financials for the fourth quarter of fiscal 2023, which is scheduled to be unveiled on January 30. Projections indicate a 40.8% year-over-year decline in revenue to $14.38 billion, with a loss per share of $0.18 for the quarter.
That being said, the company grappled with weakened demand for its COVID-19 products, including Paxlovid and Comirnaty, prompting a <a href="https://www.cnbc.com/2023/10/13/pfizer-cuts-earnings-revenue-guidance-as-covid-sales-slump.html">downward revision of its 2023 guidance</a> in October.
Beyond the fading COVID-19 revenue, the company is confronting challenges in diversifying its growth pipelines. The <a href="https://www.investopedia.com/pfizer-q4-2023-earnings-what-to-know-8548509">discontinuation of a weight-loss pill study</a> due to adverse effects underscores these hurdles. Additionally, the company contends with threats from generic competition to its Vyndaqel heart medication.
However, on December 14, 2023, PFE concluded its acquisition of Seagen Inc., bolstering its presence in revolutionary cancer treatments. Seagen's Antibody-Drug Conjugate (ADC) technology, combined with PFE's capabilities, positions the company for significant growth, especially in the critical field of oncology.
The strategic move addresses the persistent challenge of cancer, a leading cause of death, marking a transformative step for PFE. The acquisition is expected to contribute substantially to PFE's near- and long-term financial objectives, establishing a powerful foothold in the evolving landscape of cancer therapeutics.
Shares of PFE have plummeted 38.6% over the past year to close the last trading session at $28.33.
Here are the fundamental aspects of PFE that could influence its performance in the near term:
Bleak Financials
For the fiscal 2023 third quarter, PFE's revenues decreased 41.5% year-over-year to $13.23 billion. Its loss from continuing operations stood at $2.39 billion, compared to an income of $8.65 billion in the previous year's quarter.
Moreover, loss attributable to PFE common shareholders and loss per common share amounted to $2.38 billion and $0.42, compared to a net income and EPS of $8.61 billion and $1.51 in the prior year's period, respectively.
Poor Historical Growth
Over the past five years, PFE's net income decreased at a CAGR of 15.1%. Its EPS also declined at a 14.3% CAGR. Additionally, the company's levered free cash flow decreased at a CAGR of 18.4% over the same time frame.
Discounted Valuation
In terms of forward non-GAAP P/E, the stock is trading at 17.98x, 4.4% lower than the 18.80x industry average. Its forward <a href="https://www.investopedia.com/terms/e/enterprisevaluesales.asp">EV/Sales</a> of 2.97x is 21.4% lower than the industry average of 3.77x. Furthermore, the stock's forward Price/Sales of 2.62x, 34.1% lower than the 3.98x industry average.
Optimistic Analyst Estimates for Fiscal 2024
The consensus revenue estimate of $60.50 billion for the fiscal year ending December 2024 indicates a 2.4% year-over-year increase. Likewise, the consensus EPS estimate of $2.22 for the ongoing year exhibits a 45.2% increase from the prior year.
Mixed Profitability
The stock's trailing-12-month gross profit margin of 68.99% is 21.2% higher than the 56.91% industry average. Its trailing-12-month EBIT margin of 25.82% compares with the 0.09% industry average. However, the stock's trailing-12-month asset turnover ratio of 0.33x is 15.3% lower than the industry average of 0.39x.
POWR Ratings
PFE's mixed outlook is apparent in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of C, which translates to Neutral in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
Our proprietary rating system also evaluates each stock based on eight distinct categories. PFE has an A grade for Value, aligning with its lower-than-industry valuation. However, it has a C grade for Quality, reflecting its moderate profitability. The stock also has an F grade for Growth, mirroring the lackluster growth of its financials.
PFE is ranked #71 out of 160 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry. <a href="https://stocknews.com/stock/PFE/">Click here</a> to access PFE's Momentum, Stability, and Sentiment ratings.
Bottom Line
PFE is currently encountering growth impediments, manifested in subdued demand for COVID-19 products and difficulties diversifying pipelines, underscored by discontinuing a weight-loss pill study due to adverse effects. Recent financial quarter performance and profitability also exhibit shortcomings.
Nevertheless, the company holds potential for long-term gains through strategic acquisitions, coupled with optimistic asset projections for fiscal 2024. In light of this, it could be wise to wait for an opportune entry point into PFE.
How Does Pfizer Inc. (PFE) Stack Up Against Its Peers?
While PFE has an overall grade of C, equating to a Neutral rating, you may check out these other A-rated (Strong Buy) stocks within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry: Novo Nordisk A/S (<a href="https://stocknews.com/stock/NVO/">NVO</a>), Novartis AG (<a href="https://stocknews.com/stock/NVS/">NVS</a>) and Santen Pharmaceutical Co., Ltd. (<a href="https://stocknews.com/stock/SNPHY/">SNPHY</a>). To explore more Medical – Pharmaceuticals stocks, <a href="https://stocknews.com/category/pharmaceuticals/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>

<hr />
PFE shares rose $0.03 (+0.11%) in premarket trading Monday. Year-to-date, PFE has declined -3.15%, versus a 2.55% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/pfe-nvo-nvs-snphy-pfizer-pfe-pre-earnings-strategies/>Pfizer (PFE): Pre-Earnings Strategies</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Pfizer (PFE): Pre-Earnings Strategies

Santen Pharmaceutical reports Q3 results

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. Over the past year, Santen's share price rose about 32% from $7.60 to $10.01 as of Thursday's market close

Current Analysis: Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. reports FY results

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Santen Pharmaceutical (OTCMKTS:<a href="https://investorplace.com/stock-quotes/snphy-stock-quote/">SNPHY</a>) just reported results for the fourth quarter of 2023.<ul><li>Santen Pharmaceutical reported earnings per share of 16 cents.</li><li>The company reported revenue of $533.27 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/snphy-stock-earnings-santen-pharmaceutical-for-q4-of-2023/">SNPHY Stock Earnings: Santen Pharmaceutical Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Comments

Santen Pharmaceutical

Vendite allo scoperto

Santen Pharmaceutical (OTC:SNPHY) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO